Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04290676 · ClinicalTrials.gov registry record
DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001
A clinical trial, sponsored by EyePoint Pharmaceuticals.
- Completed
- Registry status
- 527
- Enrollment target
NCT04290676 is a clinical trial that has completed, run by EyePoint Pharmaceuticals. The registered enrollment target is 527 participants.
The verdict
NCT04290676 has completed, sponsored by EyePoint Pharmaceuticals.
- COMPLETED
- Registry status
- 527 participants
- Enrollment target
Study Summary
Retrospective study to provide clinical outcomes with DEXYCU (dexamethasone intraocular suspension) 9%.
Interventions
- DRUG DEXYCU (dexamethasone intraocular suspension) 9%.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 527 participants |
| Start Date | 2019-11-13 |
| Est. Completion | 2020-05-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04290676
The ClinicalTrials.gov registry entry for NCT04290676 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 527 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EyePoint Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DEXYCU (dexamethasone intraocular suspension) 9%. is the first listed.
NCT04290676 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04290676 about?
NCT04290676 is a clinical study titled "DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001". Retrospective study to provide clinical outcomes with DEXYCU (dexamethasone intraocular suspension) 9%.
What is the current status of trial NCT04290676?
This trial is currently completed. The enrollment target is 527 participants. The study started on 2019-11-13. Estimated completion is 2020-05-01.
What interventions are being tested in trial NCT04290676?
The interventions under investigation include: DEXYCU (dexamethasone intraocular suspension) 9%. (DRUG).
Who is sponsoring clinical trial NCT04290676?
This trial is sponsored by EyePoint Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.